Back

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps

Paes Dias, M.; Tripathi, V.; Heijden, I. v. d.; Cong, K.; Manolika, E.-M.; Bhin, J.; Gogola, E.; Galanos, P.; Annunziato, S.; Lieftink, C.; Andujar-Sanchez, M.; Chakrabarty, S.; Smith, G. C. M.; Ven, M. v. d.; Beijersbergen, R. L.; Bartkova, J.; Rottenberg, S.; Cantor, S.; Bartek, J.; Chaudhuri, A. R.; Jonkers, J.

2021-07-20 cancer biology
10.1101/2021.03.24.436323 bioRxiv
Show abstract

Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, preclinical and clinical research with PARPi has revealed multiple resistance mechanisms, highlighting the need for identification of novel functional biomarkers and combination treatment strategies. Functional genetic screens performed in cells and organoids that acquired resistance to PARPi by loss of 53BP1 identified loss of LIG3 as an enhancer of PARPi toxicity in BRCA1-deficient cells. Enhancement of PARPi toxicity by LIG3 depletion is dependent on BRCA1 deficiency but independent of the loss of 53BP1 pathway. Mechanistically, we show that LIG3 loss promotes formation of MRE11-mediated post-replicative ssDNA gaps in BRCA1-deficient and BRCA1/53BP1 double-deficient cells exposed to PARPi, leading to an accumulation of chromosomal abnormalities. LIG3 depletion also enhances efficacy of PARPi against BRCA1-deficient mammary tumors in mice, suggesting LIG3 as a potential therapeutic target.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cell Reports
○ 1498 papers in training set
Top 0.6%
15.0%
Similar papers in this journal
2
Molecular Cell
○ 350 papers in training set
Top 0.3%
13.0%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 18%
9.7%
Similar papers in this journal
4
eLife
● 5828 papers in training set
Top 14%
7.8%
Similar papers in this journal
5
Developmental Cell
○ 196 papers in training set
Top 0.4%
6.7%
Similar papers in this journal
50% of probability mass above
6
EMBO Reports
○ 263 papers in training set
Top 0.5%
5.5%
7
Science Advances
● 1243 papers in training set
Top 5%
5.1%
8
The EMBO Journal
○ 309 papers in training set
Top 0.9%
4.3%
9
Journal of Experimental Medicine
● 119 papers in training set
Top 0.8%
3.2%
10
Cancer Discovery
● 66 papers in training set
Top 1.0%
2.4%
11
Genes & Development
● 90 papers in training set
Top 0.5%
2.4%
12
Nature Cell Biology
○ 118 papers in training set
Top 1%
2.4%
13
Nucleic Acids Research
◐ 1281 papers in training set
Top 9%
1.7%
14
iScience
○ 1154 papers in training set
Top 19%
1.7%
15
Cancer Research
● 130 papers in training set
Top 2%
1.3%
16
Cell
○ 431 papers in training set
Top 7%
1.3%
17
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 35%
1.1%
18
Cell Death & Differentiation
○ 48 papers in training set
Top 0.8%
1.1%
19
Life Science Alliance
● 285 papers in training set
Top 8%
0.8%
20
Oncogene
○ 85 papers in training set
Top 2%
0.8%
21
Communications Biology
○ 993 papers in training set
Top 30%
0.8%
22
Journal of Cell Biology
● 392 papers in training set
Top 4%
0.8%
23
PLOS Genetics
● 862 papers in training set
Top 13%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.